This Ask the Expert special issue offers information on the use of durvalumab for the first-line treatment of advanced biliary tract cancers. It features expert insights on efficacy results from the TOPAZ-1 clinical trial, the prevalence of genomic alterations and associated outcomes in the biomarker-evaluable patient population, and strategies for community healthcare providers who are looking to incorporate this treatment into their practice.
